» Articles » PMID: 1696204

Effect of Interleukin 3 on Cytosine Arabinoside-mediated Cytotoxicity of Leukemic Myeloblasts

Overview
Journal Exp Hematol
Specialty Hematology
Date 1990 Aug 1
PMID 1696204
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The concept of biologic modification of proliferation and differentiation of myeloid leukemia cells has attracted much attention over the past years. One promising strategy involves the recruitment of leukemic cells into the cell cycle by hematopoietic growth factors in combination with cycle-specific cytotoxic drugs. Because cytosine arabinoside (Ara-C), which targets only cells in S-phase of the mitotic cell cycle, is included in most chemotherapeutic regimens for the treatment of acute myelogenous leukemia, we explored the hypothesis that the recruitment of quiescent immature leukemic blasts into the cell cycle by the early acting growth factor interleukin 3 (IL-3) can increase the efficacy of Ara-C for kill of leukemic stem cells. We show that IL-3 increases the fraction of blasts in S-phase, as assessed by DNA histogram analysis with propidium iodide staining, leading to an enhancement of kill of clonogenic blast cells when combined with Ara-C. Expression of the protooncogenes c-myc, c-fms, and c-fos, known to be linked to cellular proliferation and differentiation, was also altered by IL-3 in Ara-C-treated cultures, further substantiating the role that IL-3 plays as an enhancer of the cytotoxicity of Ara-C.

Citing Articles

Glyceraldehyde 3-phosphate dehydrogenase depletion induces cell cycle arrest and resistance to antimetabolites in human carcinoma cell lines.

Phadke M, Krynetskaia N, Mishra A, Krynetskiy E J Pharmacol Exp Ther. 2009; 331(1):77-86.

PMID: 19628630 PMC: 2766228. DOI: 10.1124/jpet.109.155671.


Evolution of the arabinosides and the pharmacology of fludarabine.

Plunkett W, Gandhi V Drugs. 1994; 47 Suppl 6:30-8.

PMID: 7525187 DOI: 10.2165/00003495-199400476-00006.


In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity.

van der Lely N, de Witte T, Wessels J, Raymakers R, Muus P, Preijers F Ann Hematol. 1994; 68(5):225-32.

PMID: 7517190 DOI: 10.1007/BF01737421.


The role of colony-stimulating factors in acute leukemia.

Herrmann F, Vellenga E J Cancer Res Clin Oncol. 1990; 116(3):275-82.

PMID: 2196263 DOI: 10.1007/BF01612903.


Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group.

Gerhartz H, Marcus R, Delmer A, Zwierzina H, de Witte T, Jacobs A Infection. 1992; 20 Suppl 2:S116-23.

PMID: 1493935 DOI: 10.1007/BF01705030.